Baxdrostat Win; Medicare Covers TriClip TEER; AI Flags Cardiac Amyloidosis

(MedPage Today) -- AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, successfully lowered blood pressure (BP) in people with uncontrolled or treatment-resistant hypertension in the BaxHTN trial.
Bedtime antihypertensives...